All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Bevacizumab
Therapeutic Area: Oncology Product Name: Byvasda
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Etana Biotechnologies
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 19, 2021
Details:
Etana is committed to launch BYVASDA® in the local market. In return, Innovent will receive milestones for development and commercialization as well as double-digit royalties on net sales.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Bevacizumab
Therapeutic Area: Oncology Product Name: Byvasda
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 28, 2020
Details:
BYVASDA® (bevacizumab biosimilar), a recombinant humanized anti-VEGF monoclonal antibody drug independently developed by Innovent, has been officially approved by the NMPA of China for the treatment of adult recurrent glioblastoma.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Orelabrutinib
Therapeutic Area: Oncology Product Name: ICP-022
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 27, 2020
Details:
Orelabrutinib is a highly selective and novel BTK inhibitor developed by InnoCare that can avoid off-target-related adverse events with improved safety and efficacy.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Ropeginterferon ALFA-2B
Therapeutic Area: Oncology Product Name: P1101
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2020
Details:
Five-year data from the PROUD-PV/CONTINUATION-PV studies demonstrates the shortand long-term effects of ropeginterferon alfa-2b among PV patients.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Denosumab
Therapeutic Area: Oncology Product Name: Xgeva
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Amgen Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 19, 2020
Details:
The approval of XGEVA for the prevention of SREs in patients with bone metastasis from solid tumors and MM was based on clinical results from four randomized international trials that enrolled over 7,000 patients.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Ivosidenib
Therapeutic Area: Oncology Product Name: Tibsovo
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Agios Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 10, 2020
Details:
Ivosidenib, an oral, targeted inhibitor of the IDH1 enzyme, is globally the first and only US FDA-approved therapy for patients with R/R AML and an IDH1 mutation. Ivosidenib was developed by Agios Pharmaceuticals.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Ropeginterferon ALFA-2B
Therapeutic Area: Oncology Product Name: Besremi
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 04, 2020
Details:
Findings from “Long-Term Use of Ropeginterferon Alpha-2b in Polycythemia Vera: 5-Year Results from a Randomized Controlled Study and Its Extension” will be featured as an oral presentation at the Virtual ASH Annual Meeting.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Rituximab
Therapeutic Area: Oncology Product Name: Halpryza
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 09, 2020
Details:
Halpryza (rituximab injection) is Innovent’s fourth monoclonal antibody drug approved by the NMPA following TYVYT® (sintilimab injection), BYVASDA® (bevacizumab injection) and SULINNO® (adalimumab injection).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Sintilimab
Therapeutic Area: Oncology Product Name: Tyvyt
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: Undisclosed Upfront Cash: $200.0 million
Deal Type: Collaboration October 07, 2020
Details:
Innovent Biologics announce the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act, in connection with global expansion collaboration agreement between the company and Eli Lilly for TYVYT (sintilimab injection).
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
